Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126249591 | 12624959 | 1 | I | 2012 | 20160801 | 20160805 | 20160805 | EXP | BE-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023857 | GLENMARK | ROCHE N A, BLONDEEL P N, VERMEERSCH H F, PEETERS P C, LEMMENS G M, DE CUBBER J ET AL. LONG-TERM MULTIFUNCTIONAL OUTCOME AND RISKS OF FACE VASCULARIZED COMPOSITE ALLOTRANSPLANTATION. THE JOURNAL OF CRANIOFACIAL SURGERY. 2015;26 (7):2038-2046 | 0.00 | Y | 0.00000 | 20160805 | MD | BE | BE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126249591 | 12624959 | 1 | PS | Voriconazole Tablets | VORICONAZOLE | 1 | Oral | 200 MG, BID | 203503 | 200 | MG | BID | |||||||
| 126249591 | 12624959 | 2 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | Intravenous (not otherwise specified) | UNK | 0 | ||||||||||
| 126249591 | 12624959 | 3 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | Unknown | 4 MG, QD | 0 | 4 | MG | ||||||||
| 126249591 | 12624959 | 4 | SS | MYCOPHENOLATE MOFETIL. | MYCOPHENOLATE MOFETIL | 1 | Unknown | 500 MG, BID | U | 0 | 500 | MG | BID | ||||||
| 126249591 | 12624959 | 5 | SS | TACROLIMUS. | TACROLIMUS | 1 | Unknown | 0.5 MG, BID | U | 0 | .5 | MG | BID | ||||||
| 126249591 | 12624959 | 6 | C | COTRIMOXAZOLE | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | UNK, BID | 0 | BID | |||||||||
| 126249591 | 12624959 | 7 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 500 MG, BID | 0 | 500 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126249591 | 12624959 | 1 | Aspergillus infection |
| 126249591 | 12624959 | 2 | Immunosuppression |
| 126249591 | 12624959 | 4 | Immunosuppression |
| 126249591 | 12624959 | 5 | Immunosuppression |
| 126249591 | 12624959 | 6 | Pseudomonas infection |
| 126249591 | 12624959 | 7 | Glucose tolerance impaired |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126249591 | 12624959 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126249591 | 12624959 | Inappropriate antidiuretic hormone secretion |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126249591 | 12624959 | 1 | 2012 | 2012 | 0 | |
| 126249591 | 12624959 | 7 | 2012 | 0 |